目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key sources of secondary data
2.1.1.2 Key objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET SIZE ESTIMATION
2.2.1.1 Revenue share analysis (bottom-up approach)
2.2.1.2 Secondary data
2.2.1.3 Primary interviews and MnM repository analysis
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
3.3 DISRUPTIVE TRENDS SHAPING IMMUNOHISTOCHEMISTRY MARKET
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

4 PREMIUM INSIGHTS
4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW
4.2 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION AND COUNTRY, 2024
4.3 IMMUNOHISTOCHEMISTRY PRODUCTS MARKET SHARE, BY END USER, 2024
4.4 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.5 UNMET NEEDS & WHITE SPACES
4.6 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.7 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
4.8 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.9 VC/PRIVATE EQUITY INVESTMENT TRENDS
4.10 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing adoption of companion diagnostics
5.2.1.2 Favorable reimbursement coverage for immunohistochemistry tests
5.2.1.3 Growing focus on digital pathology
5.2.2 RESTRAINTS
5.2.2.1 Adoption of alternative technologies in molecular diagnostics and research
5.2.2.2 Highly consolidated global market
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for precision/personalized medicines
5.2.3.2 High growth opportunities in emerging economies
5.2.3.3 Integration of AI in immunohistochemistry
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory requirements for tissue diagnostic instruments and consumables
5.2.4.2 Lack of preanalytical and analytical method standardization
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF IMMUNOHISTOCHEMISTRY PRODUCTS, BY KEY PLAYER, 2022-2024
5.4.2 AVERAGE SELLING PRICE TREND OF IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2022-2024
5.5 TECHNOLOGY ANALYSIS
5.5.1 KEY TECHNOLOGIES
5.5.1.1 Automated immunohistochemistry systems
5.5.1.2 Multiplex immunohistochemistry
5.5.2 COMPLEMENTARY TECHNOLOGIES
5.5.2.1 Chromogenic detection
5.5.2.2 Fluorescent detection
5.5.3 ADJACENT TECHNOLOGIES
5.5.3.1 In situ hybridization
5.6 PATENT ANALYSIS
5.6.1 METHODOLOGY
5.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
5.6.3 LIST OF KEY PATENTS
5.7 TRADE ANALYSIS
5.7.1 IMPORT DATA FOR HS CODE 3822.00, 2020-2024
5.7.2 EXPORT DATA FOR HS CODE 3822.00, 2020-2024
5.8 VALUE CHAIN ANALYSIS
5.9 ECOSYSTEM ANALYSIS
5.9.1 ROLE IN ECOSYSTEM
5.10 PORTER'S FIVE FORCES ANALYSIS
5.10.1 INTENSITY OF COMPETITIVE RIVALRY
5.10.2 BARGAINING POWER OF SUPPLIERS
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 THREAT OF SUBSTITUTES
5.10.5 THREAT OF NEW ENTRANTS
5.11 KEY STAKEHOLDERS & BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.11.2 KEY BUYING CRITERIA
5.12 TARIFF & REGULATORY ANALYSIS
5.12.1 TARIFF DATA ANALYSIS
5.12.2 REGULATORY LANDSCAPE
5.12.2.1 North America
5.12.2.1.1 US
5.12.2.1.2 Canada
5.12.2.2 Europe
5.12.2.3 Asia Pacific
5.12.2.3.1 Japan
5.12.2.3.2 China
5.12.2.3.3 India
5.12.2.4 Latin America
5.12.2.4.1 Brazil
5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 KEY CONFERENCES & EVENTS, 2025-2026
5.14 INVESTMENT & FUNDING SCENARIO
5.15 IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET
5.16 IMPACT OF 2025 US TARIFF ON IMMUNOHISTOCHEMISTRY MARKET
5.16.1 KEY TARIFF RATES
5.16.2 PRICE IMPACT ANALYSIS
5.16.3 IMPACT ON KEY COUNTRIES/REGIONS
5.16.3.1 North America
5.16.3.1.1 US
5.16.3.2 Europe
5.16.3.3 Asia Pacific
5.16.3.4 Rest of the World
5.16.4 IMPACT ON END-USE INDUSTRIES
5.16.4.1 Pharmaceutical & biopharmaceutical companies
5.16.4.2 Hospitals & clinics
5.16.4.3 Academic & research institutes
5.16.4.4 Contract research organizations

6 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 ANTIBODIES
6.2.1 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE
6.2.1.1 Primary antibodies
6.2.1.1.1 Increasing adoption of targeted immunotherapy and custom antibody development to drive segment
6.2.1.2 Secondary antibodies
6.2.1.2.1 Better signal amplification and easier manufacturing process to fuel segment growth
6.2.2 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY
6.2.2.1 Monoclonal antibodies
6.2.2.1.1 Increased applications in cancer diagnostics to support segment growth
6.2.2.2 Polyclonal antibodies
6.2.2.2.1 Better sensitivity and higher resistance to changes in antigen conformation to augment segment growth
6.2.3 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS
6.2.3.1 Class I/II assay antibodies
6.2.3.1.1 Focus on precision medicine and standardized reagents to favor segment growth
6.2.3.2 Class III assay antibodies
6.2.3.2.1 Expansion of targeted therapies to augment segment growth
6.3 REAGENTS
6.3.1 BLOCKING SERA & REAGENTS
6.3.1.1 Need to prevent non-specific binding and provide accurate outcomes to drive adoption
6.3.2 CHROMOGENIC SUBSTRATES
6.3.2.1 Rapid detection and faster diagnosis to propel segment growth
6.3.3 FIXATION REAGENTS
6.3.3.1 Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption
6.3.4 ORGANIC SOLVENTS
6.3.4.1 Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market
6.3.5 PROTEOLYTIC ENZYMES
6.3.5.1 Proteolytic enzymes to improve accessibility of target antibodies and DNA
6.3.6 DILUENTS
6.3.6.1 Need for reducing non-specific background staining during immunostaining to aid segment growth
6.3.7 OTHER REAGENTS
6.4 KITS
6.4.1 HUMAN IMMUNOHISTOCHEMISTRY KITS
6.4.1.1 Increasing focus on cancer research to fuel segment growth
6.4.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS
6.4.2.1 Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth
6.5 INSTRUMENTS & SOFTWARE
6.5.1 IHC STAINERS
6.5.1.1 Increased availability of automated IHC stainers to fuel segment growth
6.5.2 SAMPLE PREPARATION INSTRUMENTS
6.5.2.1 Tissue processors
6.5.2.1.1 Rising biopsy volumes and increasing workflow automation to fuel segment growth
6.5.2.2 Microtomes
6.5.2.2.1 High precision demand and increased workforce challenges to aid segment growth
6.5.2.3 Other sample preparation instruments
6.5.3 IMAGE ANALYSIS INSTRUMENTS
6.5.3.1 Escalating demand for objective and reproducible quantification of IHC-stained tissue to boost segment growth
6.6 SERVICES
6.6.1 INCREASED COMPLEXITY OF BIOMARKER REQUIREMENTS AND EXPANSION OF GLOBAL CLINICAL TRIALS TO AID MARKET GROWTH

7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DIAGNOSTIC APPLICATIONS
7.2.1 CANCER
7.2.1.1 Automation, AI-enhanced quantitation, and multiplexing to accelerate global cancer IHC adoption
7.2.2 INFECTIOUS DISEASES
7.2.2.1 Multiplex pathogen panels, automation, and AI-driven imaging to boost market growth
7.2.3 AUTOIMMUNE DISEASES
7.2.3.1 Focus on AI-powered multiplex imaging and automated analysis to propel market growth
7.2.4 NEPHROLOGICAL DISEASES
7.2.4.1 Better understanding of novel renal biomarkers and virtual multiplexing to accelerate market growth
7.2.5 NEUROLOGICAL DISEASES
7.2.5.1 Advances in neuroimmunopathology, novel biomarker discovery, multiplexing, and AI-supported image analysis to drive market
7.2.6 OTHER DIAGNOSTIC APPLICATIONS
7.3 RESEARCH APPLICATIONS
7.3.1 DRUG DEVELOPMENT & TESTING
7.3.1.1 AI-enabled quantitation, regulatory support, and organ-on-chip integration to propel growth in drug development
7.3.2 OTHER RESEARCH APPLICATIONS
7.4 FORENSIC APPLICATIONS
7.4.1 ADVANCEMENTS IN VALIDATED INJURY AND DEATH MARKERS WITH IHC INTEGRATION IN FORENSIC IMAGING TO DRIVE MARKET

8 IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS & DIAGNOSTIC LABORATORIES
8.2.1 EXPANSION OF DIAGNOSTIC INFRASTRUCTURE AND DIGITAL AUTOMATION TO DRIVE GLOBAL MARKET GROWTH
8.3 ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS
8.3.1 INNOVATION IN MULTIPLEX AND AI-ENABLED IMMUNOHISTOCHEMISTRY TO FUEL GLOBAL MARKET EXPANSION
8.4 OTHER END USERS

9 IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 INTEGRATION OF MULTIPLEX IHC SERVICES WITH REGULATORY-CLEARED WORKFLOWS TO AUGMENT MARKET GROWTH
9.3 ACADEMIC INSTITUTIONS
9.3.1 ADOPTION OF MULTIPLEX SPATIAL IMMUNOHISTOCHEMISTRY AND DIGITAL PATHOLOGY TO BOOST MARKET GROWTH

10 IMMUNOHISTOCHEMISTRY MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 US to dominate North American immunohistochemistry market during forecast period
10.2.3 CANADA
10.2.3.1 High incidence of cancer and increased demand for advanced diagnostics to propel market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 High investments in life science R&D and favorable reimbursement policies to drive market
10.3.3 UK
10.3.3.1 Rising prevalence of cancer and increasing government funding in healthcare research to augment market growth
10.3.4 FRANCE
10.3.4.1 Increased research in cancer diagnosis and treatment to support market growth
10.3.5 ITALY
10.3.5.1 Advanced healthcare infrastructure and high geriatric population to fuel market growth
10.3.6 SPAIN
10.3.6.1 Increased demand for personalized medicines to boost adoption of immunohistochemistry products
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Rising healthcare investments and increasing cancer burden to spur market growth
10.4.3 JAPAN
10.4.3.1 High geriatric population and increased government healthcare expenditure to support market growth
10.4.4 INDIA
10.4.4.1 Need for high-end pathology and diagnostic services to propel market growth
10.4.5 AUSTRALIA
10.4.5.1 Increased patient population and high demand for quality healthcare to aid market growth
10.4.6 SOUTH KOREA
10.4.6.1 Focus on precision healthcare and personalized medicines to drive market
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth
10.5.3 MEXICO
10.5.3.1 Increasing research initiatives and rising cancer cases to drive market
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
10.6.2 GCC COUNTRIES
10.6.2.1 Kingdom of Saudi Arabia
10.6.2.1.1 Growing cancer burden and increasing focus on oncology-based research programs to augment market growth
10.6.2.2 UAE
10.6.2.2.1 Favorable government initiatives and high investments in healthcare infrastructure to fuel market growth
10.6.2.3 Rest of GCC Countries
10.6.3 REST OF MIDDLE EAST
10.7 AFRICA
10.7.1 RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET
10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET
11.3 REVENUE ANALYSIS, 2020-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Offering footprint
11.5.5.4 Application footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.6.5.1 Detailed list of key startups/SMEs
11.6.5.2 Competitive benchmarking of key startups/SMEs
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.7.1 FINANCIAL METRICS
11.7.2 COMPANY VALUATION
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT APPROVALS
11.9.2 DEALS
11.9.3 EXPANSIONS
11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE LTD.
12.1.1.1 Business overview
12.1.1.2 Products/Services offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches and approvals
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 DANAHER CORPORATION
12.1.2.1 Business overview
12.1.2.2 Products/Services offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches and approvals
12.1.2.3.2 Deals
12.1.2.4 MnM view
12.1.2.4.1 Key strengths
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 AGILENT TECHNOLOGIES, INC.
12.1.3.1 Business overview
12.1.3.2 Products/Services offered
12.1.3.3 Recent developments
12.1.3.3.1 Product approvals
12.1.3.3.2 Deals
12.1.3.3.3 Expansions
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 PHC HOLDINGS CORPORATION
12.1.4.1 Business overview
12.1.4.2 Products/Services offered
12.1.4.3 Recent developments
12.1.4.3.1 Deals
12.1.4.4 MnM view
12.1.4.4.1 Key strengths
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses & competitive threats
12.1.5 THERMO FISHER SCIENTIFIC INC.
12.1.5.1 Business overview
12.1.5.2 Products/Services offered
12.1.5.3 MnM view
12.1.5.3.1 Key strengths
12.1.5.3.2 Strategic choices
12.1.5.3.3 Weaknesses & competitive threats
12.1.6 MERCK KGAA
12.1.6.1 Business overview
12.1.6.2 Products/Services offered
12.1.7 BIO-RAD LABORATORIES, INC.
12.1.7.1 Business overview
12.1.7.2 Products/Services offered
12.1.8 BIO-TECHNE
12.1.8.1 Business overview
12.1.8.2 Products/Services offered
12.1.8.3 Recent developments
12.1.8.3.1 Deals
12.1.8.3.2 Other developments
12.1.9 BECTON, DICKINSON AND COMPANY (BD)
12.1.9.1 Business overview
12.1.9.2 Products/Services offered
12.1.10 TAKARA BIO INC.
12.1.10.1 Business overview
12.1.10.2 Products/Services offered
12.1.11 ENZO BIOCHEM INC.
12.1.11.1 Business overview
12.1.11.2 Products/Services offered
12.1.11.3 Recent developments
12.1.11.3.1 Expansions
12.1.12 SINO BIOLOGICAL, INC.
12.1.12.1 Business overview
12.1.12.2 Products/Services offered
12.1.13 SAKURA FINETEK JAPAN CO., LTD.
12.1.13.1 Business overview
12.1.13.2 Products/Services offered
12.1.13.3 Recent developments
12.1.13.3.1 Product launches
12.1.13.3.2 Deals
12.1.14 CELL SIGNALING TECHNOLOGY, INC.
12.1.14.1 Business overview
12.1.14.2 Products/Services offered
12.1.14.3 Recent developments
12.1.14.3.1 Deals
12.1.15 BIO SB
12.1.15.1 Business overview
12.1.15.2 Products/Services offered
12.1.15.3 Recent developments
12.1.15.3.1 Product launches
12.1.16 MILTENYI BIOTEC
12.1.16.1 Business overview
12.1.16.2 Products/Services offered
12.1.17 ORIGENE TECHNOLOGIES, INC.
12.1.17.1 Business overview
12.1.17.2 Products/Services offered
12.2 OTHER PLAYERS
12.2.1 EAGLEBIO
12.2.2 BIOCARE MEDICAL, LLC
12.2.3 ELABSCIENCE
12.2.4 BIOGENEX
12.2.5 DIAGNOSTIC BIOSYSTEMS INC.
12.2.6 HISTO-LINE LABORATORIES
12.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
12.2.8 CANDOR BIOSCIENCE GMBH
12.2.9 GENEMED BIOTECHNOLOGIES, INC.

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS